 |
| Attached files |
| File | Filename |
|---|
| EX-31.1 - EX-31.1 - BG Medicine, Inc. | d398643dex311.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R3.htm |
| 10-Q - FORM 10-Q - BG Medicine, Inc. | d398643d10q.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R20.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R13.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R15.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R7.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R8.htm |
| EXCEL - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc. | R9.htm |
| EX-32 - EX-32 - BG Medicine, Inc. | d398643dex32.htm |
| EX-31.2 - EX-31.2 - BG Medicine, Inc. | d398643dex312.htm |
| EX-10.2 - EX-10.2 - BG Medicine, Inc. | d398643dex102.htm |
| EX-10.1 - EX-10.1 - BG Medicine, Inc. | d398643dex101.htm |
v2.4.0.6
|
Significant Accounting Policies (Details 2)
|
9 Months Ended |
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
Options to purchase common stock [Member]
|
|
|
| Common shares excluded from the computation of diluted net loss per share attributable to common stockholders |
|
|
| Antidilutive securities excluded from computation of earnings per share |
2,784,777 |
3,202,391 |
|
Common Stock Warrant Liability [Member]
|
|
|
| Common shares excluded from the computation of diluted net loss per share attributable to common stockholders |
|
|
| Antidilutive securities excluded from computation of earnings per share |
1,086,343 |
1,249,001 |
| X |
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
+ Details
| Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by BG Medicine, Inc. and has no official or unofficial affiliation with BG Medicine, Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
